Combining DNA sequencing, RNA sequencing and cytosine methylation profiling in serial samples from 60 IDH1- or IDH2-mutant AML patients treated with an IDH inhibitor, they showed leukemia stemness to be a major driver of primary resistance to IDH inhibition. The gene discussed is IDH2; the disease is leukemia.